Zentek Ltd Stock Price, News & Analysis

Zentek Ltd. (Nasdaq:ZTEK) has executed a property purchase agreement with its subsidiary, Albany Graphite Corp., to transfer the Albany Graphite Project. Albany will issue 59,999,900 common shares to Zentek in exchange for the ownership of the project, which includes mining claims and related assets. Albany plans to raise funds through a non-brokered private placement at $1.00 per subscription receipt, which will convert into common shares and warrants upon certain conditions being met. The funds will support community engagement, environmental studies, and an updated technical report. The Albany Graphite Project, located in Ontario, aims to supply a critical mineral for the Electric Vehicle industry, anticipating increased demand as projections suggest significant graphite production deficits in the coming decade.

Zentek Ltd. (NASDAQ: ZTEK, TSXV: ZEN) has announced the grant of 600,000 stock options to its directors, officers, and employees, exercisable at a price of $2.12 per share. The options will vest in stages over varying periods: one-third immediately, one-third after six months, and one-third after one year for executives, while others will vest one-third immediately, one-third after one year, and one-third after two years. This grant is part of the company’s annual compensation review. Zentek is a graphene technology company that develops products aimed at enhancing safety and performance, including the antimicrobial ZenGUARD™ coating, which has shown 99% efficacy against pathogens. The company’s production facility is in Guelph, Ontario. Further details can be found on their website and SEDAR profile.

Zentek Ltd. (NASDAQ:ZTEK) has filed patent applications for its antimicrobial technology, ZenGUARD, in 47 new jurisdictions, including the US and Europe. The patent examiner confirmed that ZenGUARD meets all requirements for patentability, including novelty and industrial applicability. This technology enhances the filtration efficiency of surgical masks and HVAC filters while exhibiting 99% antimicrobial activity. Zentek aims to commercialize ZenGUARD, asserting that it can provide significant competitive advantages to partners. The company also plans to pursue patents for additional technologies like ZenARMOR, focused on corrosion protection.

Zentek Ltd. (NASDAQ:ZTEK) has signed an agreement with Arka BRENStech Pvt Ltd to explore business opportunities in India, specifically targeting sales and distribution of Zentek's masks and HVAC filters. BRENStech will assist with regulatory navigation and connect Zentek with potential manufacturing partners. The Indian PPE market is valued at $1 billion USD, and Zentek has already shipped 2.1 million masks to support initial sales. With India's economy projected to become the 3rd largest by 2030 and a growing middle class, Zentek aims for significant growth in the region.

Zentek Ltd. (Nasdaq:ZTEK; TSXV:ZEN) announced successful antimicrobial testing for its ZenGUARD™-coated masks conducted by SGS. The testing showed over 99.99% bacterial filtration efficiency after just one hour. Specifically, the mask effectively reduced Escherichia Coli CFU from 260,000 to under 100. Additionally, ZenGUARD™ demonstrated 86.7% antiviral efficiency within one hour against H1N1, increasing to 99.7% after eight hours. These results highlight the potential of ZenGUARD™ to enhance safety for healthcare providers and patients in high-risk environments.

Zentek Ltd. (Nasdaq:ZTEK; TSX-V:ZEN) will have its CEO, Greg Fenton, present at the Industrial Tech Virtual Conference on March 21, 2023, at 2 p.m. ET. Hosted by Maxim Group LLC and available on M-Vest.com, the conference will address emerging technological trends in industrial sectors. Topics include drones, water infrastructure, solar project development, and clean energy technology. Zentek specializes in graphene and nanomaterials for healthcare applications, notably its ZenGUARD™ product, which demonstrates 99% antimicrobial efficacy. For more information, visit Zentek.com.